ScandiDos FCF Margin
The Free Cash Flow Margin of ScandiDos (SDOS.ST) as of Jul 29, 2026 is -12.53 %. In the previous year, Free Cash Flow Margin was -4.49 % — a change of 179.09% (lower).
Get this data via API
Financial Data API
FCF Margin
-12.53 %
YoY
179.09%
Last updated:
Free Cash Flow Margin of ScandiDos is 2026 -12.53 % . Free Cash Flow Margin of ScandiDos was 2025 -4.49 % . It decreases by 179.09% lower compared to the previous year.
Access this data via the Eulerpool API
ScandiDos Stock analysis
What does ScandiDos do? ScandiDos AB is a leading company in the field of medical technology based in Uppsala, Sweden. The company was founded in 2002 and specializes in the development of innovative solutions for radiation therapy. ScandiDos AB is a subsidiary of ScandiDos Inc., a US-based company located in Madison, Wisconsin.
The business model of ScandiDos AB is based on the development of high-quality, innovative products for radiation therapy and the provision of excellent services for customers. The company focuses on the needs of doctors, medical professionals, and patients, with the goal of constantly optimizing and improving the quality of radiation therapy.
ScandiDos AB is divided into different divisions that focus on the specific requirements and needs of customers. One of these divisions is the development of advanced dosimeters for radiation therapy. ScandiDos AB's dosimeters are world-leading and can provide fast and precise real-time measurement of the radiation dose. They are designed for use in the radiation therapy of cancer patients and can ensure that patients receive an effective dosage that fights tumor growth while sparing the surrounding tissue.
Another important division of ScandiDos AB is the provision of training and support for customers. The company offers a wide range of training, courses, and support for doctors, business partners, and medical professionals to ensure that customers have the necessary knowledge and skills to effectively use and utilize ScandiDos AB's dosimeters and other products. The training is conducted by experienced specialists and tailored to the specific needs of customers.
ScandiDos AB's product range also includes specialized software tools for radiation therapy. This includes, for example, the Delta4® Phantom simulator, which allows for a simulation of radiation therapy to achieve the best results. In addition, ScandiDos AB offers other software tools for measuring and monitoring the radiation dose.
ScandiDos AB has an extensive network of international partners and business associates who support the company in providing its products and services. The partners are represented in various countries worldwide and ensure that ScandiDos AB's products and services are available everywhere in the world.
Overall, ScandiDos AB has become a company that focuses on quality, innovation, and customer satisfaction. The company's products and services contribute to improving the results of radiation therapy and increasing the quality of life for cancer patients worldwide. ScandiDos is one of the most popular companies on Eulerpool.
Frequently Asked Questions about ScandiDos stock
Free Cash Flow Margin of ScandiDos is -12.53 % in 2026.
Access this data via the Eulerpool API
Margins — ScandiDos
All Key Metrics — ScandiDos
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth